Page 11 - VI DERM BOOK COM (002)_FINAL

VI PEEL
proprietary blend formula

VI Peel Treatments for the face are formulated using a synergistic blend of TCA, PHENOL, RETINOIC ACID, and SALICYLIC ACID at
lower individual concentrations. This combination allows the VI Peel to penetrate the dermis without the destruction and longer healing
time that a straight acid would incur, while still achieving the same outcome. Using peeling agents in straight acid form also increases
the risk of complications. The blended VI Peel formulations add nutrients such as antioxidant vitamin C, along with ingredients for
pigment suppression and acne control, allowing our peels to address conditions that a straight acid alone cannot.

KEY INGREDIENTS:

Trichloroacetic Acid provides excellent exfoliation properties while stimulating collagen production. Its hygroscopic nature provides
efficient and effective protein denaturation.
Retinoic Acid superficially acts like an AHA, breaking bonds between desmosomes, promoting increased cellular turnover, collagen and
elastin stimulation, increasing water levels within the epidermis, and inhibiting melanogenesis inhibitor.

Salicylic Acid is a beta hydroxy acid that is a keratolytic. This is an effective anti-acne ingredient. Salicylic Acid cuts down on the
shedding of cells within the follicles, reducing impactions and acts as an anti-inflammatory agent.

Phenol can trap free radicals, works as a chemical cauterant to exfoliate the skin, has preservative properties, and is an effective
numbing agent.

Ascorbic Acid is a powerful water-soluble antioxidant that provides important protection against damage, induced by UV radiation. It
reduces erythema, acts as a tyrosinase inhibitor, and acts as an MMPi by controlling inflammatory enzymes.

Benzoyl Peroxide is a topical antibacterial used in the treatment of acne vulgaris; it also has keratolytic, sebostatic, and skin peeling
actions which promote evacuation of comedones.
Hydroquinone is a skin lightening agent, promotes providing potent melanogenesis inhibition.

Kojic Acid, found naturally, this acid aids in fighting discoloration and brightens the complexion. It is an effective melanogenesis
inhibitor because of its ability to separate copper bound to tyrosinase and decrease the number of melanosomes and dendrites that
can transfer the melanosomes.
Hydrocortisone, an anti-inflammatory that soothes, reduces redness, and inflammation.

CLINICAL ENDPOINTS: SPECIFIC TO THE VI PEEL FACE PORTFOLIO

All VI Peels are kitted with your patient safety and outcomes in mind. Each VI Peel kit includes a measured single dose of peeling
solution, a 2x2 woven gauze for application, an acetone towelette for degreasing, and a custom patient after care kit.
The following endpoints are key in assuring optimal outcomes for your patients. Achieving a clinical endpoint assures you are achieving
the therapeutic level based on your patient’s skin condition, tolerance, and response.
1. Dosage: The entire dose of the peeling solution should be used during the treatment. One dose will cover your patient’s full
face and neck.
2. Pain Level: Pain level should remain between 1-4 on a pain scale of 1-10, with 1 being very little pain and 10 being extreme
pain. Should pain level exceed 6, stop application and assess the skin response, including erythema, frosting, and swelling. If
additional symptoms are present, discontinue the treatment.
3. Erythema: Patients will have mild to moderate erythema present on the skin during application. It is expected and varies based
on patient skin condition. Should erythema become severe, stop application and reassess your patient’s skin. If additional
symptoms are present like elevated pain level or frosting, discontinue the treatment.
4. Frosting: VI Peels are intended to penetrate to the papillary dermis. With dermal penetration, frosting may occur.
A level 1 frost is acceptable for Fitzpatrick Skin Types I-IV. Should frosting deepen to a level 2, discontinue treatment
regardless of Fitzpatrick Skin Type. Level 2 frosting indicates deeper penetration than expected which will result in longer
healing time and increased risks to PIH and secondary infections.

11